Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008;122:812–24.
Google Scholar
McKenna SP, Doward LC. Quality of life of children with atopic dermatitis and their families. Curr Opin Allergy Clin Immunol. 2008;8:228–31.
Google Scholar
Fasseeh AN, Elezbawy B, Korra N, Tannira M, Dalle H, Aderian S, Abaza S, Kaló Z. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther (Heidelb). 2022;12(12):2653–68.
Google Scholar
Gonzalez-Uribe V, Vidaurri-de la Cruz H, Gomez-Nuñez A, Leyva-Calderon JA, Mojica-Gonzalez ZS. Comorbidities & burden of disease in atopic dermatitis. Asian Pac J Allergy Immunol. 2023;41(2):97–105.
Google Scholar
Barbeau M, Bpharm HL. Burden of atopic dermatitis in Canada. Int J Dermatol. 2006;45(1):31–6.
Google Scholar
Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350–8.
Google Scholar
Nomura T, Kabashima K. Advances in atopic dermatitis in 2015. J Allergy Clin Immunol. 2016;138(6):1548–55.
Google Scholar
Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:S128–39.
Tsakok T, Marrs T, Mohsin M, Baron S, du Toit G, Till S, Flohr C. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071–8.
Google Scholar
Campbell DE. Role of food allergy in childhood atopic dermatitis. J Paediatr Child Health. 2012;48(12):1058–64.
Google Scholar
Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res. 2016;8(3):181–90.
Google Scholar
Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–22.
Google Scholar
Schuler CF, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. J Allergy Clin Immunol. 2023;151:1145–54.
Google Scholar
Leung DYM, Berdyshev E, Goleva E. Cutaneous barrier dysfunction in allergic diseases. J Allergy Clin Immunol. 2020;145:1485–97.
Google Scholar
Brown SJ. What have we learned from GWAS for atopic dermatitis? J Invest Dermatol. 2021;141:19–22.
Google Scholar
Sliz E, Huilaja L, Pasanen A, Laisk T, Reimann E, Magi R, et al. Uniting biobank resources reveals novel genetic pathways modulating susceptibility for atopic dermatitis. J Allergy Clin Immunol. 2022;149:1105–e129.
Google Scholar
Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3–12.
Google Scholar
Bartemes KR, Kita H. Roles of innate lymphoid cells (ILCs) in allergic diseases: the 10-year anniversary for ILC2s. J Allergy Clin Immunol. 2021;147:1531–47.
Google Scholar
Klaeschen AS, Nümm TJ, Herrmann N, Leib N, Maintz L, Sakai T et al. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis. J Allergy Clin Immunol. 2021;147:2202-12.e8.
Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the global burden of Disease Study, 1990–2017. Br J Dermatol. 2021;184:304–9.
Google Scholar
Kelleher M, Dunn-Galvin A, Hourihane JO, Murray D, Campbell LE, McLean WH, Irvine AD. Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year. J Allergy Clin Immunol. 2015;135(4):930–5.
Google Scholar
Kelleher MM, Dunn-Galvin A, Gray C, Murray DM, Kiely M, Kenny L, McLean WH, Irvine AD, Hourihane JO. Skin barrier impairment at birth predicts food allergy at 2 years of age. J Allergy Clin Immunol. 2016;137(4):1111–6.
Google Scholar
Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144–51.
Google Scholar
Pyun BY. Natural history and risk factors of atopic dermatitis in children. Allergy Asthma Immunol Res. 2015;7:101–5.
Google Scholar
Bieber T. Mechanisms of disease: atopic dermatitis. N Engl J Med. 2008;358:1483–94.
Google Scholar
Martin PE, Eckert JK, Koplin JJ, Lowe AJ, Gurrin LC, Dharmage SC, et al. Which infants with eczema are at risk of food allergy? Results from a population-based cohort. Clin Exp Allergy. 2015;45:255–64.
Google Scholar
Hill DA, Spergel JM. The atopic march: critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120:131–7.
Google Scholar
Belgrave DC, Granell R, Simpson A, Guiver J, Bishop C, Buchan I, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014;11(10):e1001748.
Google Scholar
Tham EH, Leung DY. Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march. Allergy Asthma Immunol Res. 2019;11(1):4–15.
Google Scholar
Christensen MO, Barakji YA, Loft N, Khatib CM, Egeberg A, Thomsen SF, et al. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023;37(5):984–1003.
Google Scholar
Brough HA, Liu AH, Sicherer S, Makinson K, Douiri A, Brown SJ, et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J Allergy Clin Immunol. 2015;135(1):164–70.
Google Scholar
Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006;118:152–69.
Google Scholar
Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, Bingham EA, Finlay AY, Pembroke AC, Graham-Brown RA. The U.K. Working Party’s diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994a;131:383–96.
Google Scholar
Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. Working Party’s diagnostic criteria for atopic dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol. 1994b;131:397–405.
Google Scholar
Williams HC, Burney PG, Pembroke AC, et al. The U.K. Working Party’s diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol. 1994c;131:406–16.
Google Scholar
Gu H, Chen XS, Chen K, Yan Y, Jing H, Chen XQ, Shao CG, Ye GY. Evaluation of diagnostic criteria for atopic dermatitis: validity of the criteria of Williams et al. in a hospital-based setting. Br J Dermatol. 2001;145:428–33.
Google Scholar
Kim JS. Pediatric atopic dermatitis: the importance of food allergens. Semin Cutan Med Surg. 2008;27:156–60.
Google Scholar
Bird JA, Crain M, Varshney P. Food allergen panel testing often results in misdiagnosis of food allergy. J Pediatr. 2015;166(1):97–100.
Google Scholar
Chang A, Robison R, Cai M, Singh AM. Natural history of food-triggered atopic dermatitis and development of immediate reactions in children. J Allergy Clin Immunol Pract. 2016;4(2):229–36.
Google Scholar
Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, Brown SJ, Chen Z, Chen Y, Williams HC. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134:818–23.
Google Scholar
Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, Shigematsu Y, Yoshida K, Niizeki H, Motomura K, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824–30.
Google Scholar
Xu S, Immaneni S, Hazen GB, Silverberg JI, Paller AS, Lio PA. Cost-effectiveness of prophylactic moisturization for atopic dermatitis. JAMA Pediatr. 2017;171(2):e163909.
Google Scholar
Ní Chaoimh C, Lad D, Nico C, Puppels GJ, Wong XFCC, Common JE, Murray DM, et al. Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants-the STOP-AD randomised controlled trial. Allergy. 2023;78(4):984–94.
Google Scholar
Zhong Y, Samuel M, van Bever H, Tham EH. Emollients in infancy to prevent atopic dermatitis: a systematic review and meta-analysis. Allergy. 2022;77(6):1685–99.
Google Scholar
Ridd MJ, Santer M, MacNeill SJ, Sanderson E, Wells S, Webb D, et al. Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial. Lancet Child Adolesc Health. 2022;6:522–32.
Google Scholar
Papapostolou N, Xepapadaki P, Gregoriou S, Makris M. Atopic dermatitis and food allergy: a Complex Interplay what we know and what we would like to learn. J Clin Med. 2022;11(14):4232.
Google Scholar
Skjerven HO, Lie A, Vettukattil R, Rehbinder EM, LeBlanc M, Asarnoj A, et al. Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet. 2022;399(10344):2398–411.
Google Scholar
Bradshaw LE, Wyatt LA, Brown SJ, Haines RH, Montgomery AA, Perkin MR, et al. Emollients for prevention of atopic dermatitis: 5-year findings from the BEEP randomized trial. Allergy. 2023;78(4):995–1006.
Google Scholar
Fang Z, Li L, Zhang H, Zhao J, Lu W, Chen W. Gut microbiota, Probiotics, and their interactions in Prevention and Treatment of atopic dermatitis: a review. Front Immunol. 2021;12:720393.
Google Scholar
Hu T, Dong Y, Yang C, Zhao M, He Q. Pathogenesis of children’s allergic diseases: refocusing the role of the gut microbiota. Front Physiol. 2021;12:749544.
Google Scholar
Araya M, Morelli L, Reid G, Sanders ME, Stanton C, Pineiro M, Ben Embarek P. Guidelines for the evaluation of probiotics in food. Joint FAO/WHO Working Group Report on drafting guidelines for the evaluation of probiotics in food. 2002; 30:1–1.
Li L, Han Z, Niu X, Zhang G, Jia Y, Zhang S, He C. Probiotic supplementation for Prevention of atopic dermatitis in infants and children: a systematic review and Meta-analysis. Am J Clin Dermatol. 2019;20(3):367–77.
Google Scholar
Voigt J, Lele M. Lactobacillus rhamnosus used in the Perinatal Period for the Prevention of atopic dermatitis in infants: a systematic review and Meta-analysis of Randomized trials. Am J Clin Dermatol. 2022;23(6):801–11.
Google Scholar
Hide M, Suzuki T, Tanaka A, Aoki H. Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: a 12-month, multicenter, open-label clinical trial. J Dermatol Sci. 2019;94(3):339–45.
Google Scholar
Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI position statement: newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:61.
Google Scholar
Gittler JK, Wang JF, Orlow SJ. Bathing and associated treatments in atopic dermatitis. Am J Clin Dermatol. 2017;18(1):45–57.
Google Scholar
Cardona ID, Kempe EE, Lary C, Ginder JH, Jain N. Frequent Versus Infrequent bathing in Pediatric atopic dermatitis: a Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2020;8(3):1014–21.
Google Scholar
Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415–28.
Google Scholar
Broeders JA, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience. J Am Acad Dermatol. 2016;75(2):410–9.
Google Scholar
Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.
Google Scholar
LEO Pharma Inc. Protopic (tacrolimus ointment) product monograph. June 27, 2022.
Bausch Health, Canada Inc. Pimecrolimus (Elidel cream) product monograph. January 10, 2020.
Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat. 2010;21(1):34–44.
Google Scholar
Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, Pollock BH. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83(2):375–81.
Google Scholar
Castellsague J, Kuiper JG, Pottegård A, Anveden Berglind I, Dedman D, Gutierrez L, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (joint European longitudinal lymphoma and skin Cancer evaluation – JOELLE study). Clin Epidemiol. 2018;10:299–310.
Google Scholar
McCollum AD, Paik A, Eichenfield LF. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2010;27(5):425–36.
Google Scholar
Radovic TC, Kostovic K, Ceovic R, Mokos ZB. Topical Calcineurin Inhibitors and Malignancy Risk. Int J Cancer Manag 2017;10(4):e6173.
Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011;165(3):465 – 73.
Thaçi D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol. 2010;28(1):52–6.
Google Scholar
Canadian Dermatology Association, Position Statement TCI. May. 2018. CDA believes that topical,and ever broadening clinical experience. Accessed September 11, 2023.
Pfizer Canada ULC. Eucrisa (crisaborole ointment 2%) product monograph. August 29, 2023.
Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503.
Google Scholar
Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, et al. CARE 1 investigators. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020;21(2):275–84.
Google Scholar
Eichenfield LF, Call RS, Forsha DW, Fowler J Jr, Hebert AA, Spellman M, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641–e6495.
Google Scholar
Bakaa L, Pernica JM, Couban RJ, Tackett KJ, Burkhart CN, Leins L, et al. Bleach baths for atopic dermatitis: a systematic review and meta-analysis including unpublished data, bayesian interpretation, and GRADE. Ann Allergy Asthma Immunol. 2022;128(6):660–e6689.
Google Scholar
Sanofi-aventis Canada Inc. Dupixent (dupilumab) product monograph. May 1, 2023.
Leo Pharma Inc. Adtralza (tralokinumab) product monograph. February 3, 2023.
Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52.
Google Scholar
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. SOLO 1 and SOLO 2 investigators. Two phase 3 trials of Dupilumab versus Placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.
Google Scholar
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303.
Google Scholar
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–101.
Google Scholar
Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatol. 2020;156(2):131–43.
Google Scholar
Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567–77.
Google Scholar
Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Khokhar FA et al. Long-term efficacy of dupilumab in adults with moderate to severe AD: results from a 5-year open-label extension study (LIBERTY AD OLE). Presented at the 5th Annual Revolutionizing Atopic Dermatitis (RAD) Conference; Washington, DC, USA; April 29 –May 1, 2023.
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of Dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44–56.
Google Scholar
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–93.
Google Scholar
Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to < 6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35(2):464–75.
Google Scholar
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Participating investigators. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908–19.
Google Scholar
Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, et al. Long-term efficacy and safety of Dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through Week 52 from a phase III open-label extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365–83.
Google Scholar
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–49.
Google Scholar
Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450–63.
Google Scholar
Silverberg JI, Adam DN, Zirwas M, Kalia S, Gutermuth J, Pinter A, Pink AE, Chiricozzi A, Barbarot S, Mark T, Tindberg AM. Tralokinumab Plus Topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic Dermatitis over a 32-Week period: an ECZTRA 3 Post Hoc Analysis. Am J Clin Dermatol. 2022;23(4):547–59.
Google Scholar
Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC, et al. Efficacy and safety of Tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol. 2023;159(6):596–605.
Google Scholar
Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815–24.
Google Scholar
Reich K, Simpson E, Langley R, Warren R, Costanzo A, Saeki H, et al. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN: J Cutan Med. 2023;7(2):s143.
Wollenberg A, Beck LA, de Bruin Weller M, Simpson EL, Imafuku S, Boguniewicz M, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453–65.
Google Scholar
Pfizer Canada ULC. CIBINQO (abrocitinib) product monograph. June 30, 2023.
AbbVie Corporation. RINVOQ (upadacitinib) product monograph. July 19, 2023.
Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462(1):1–13.
Google Scholar
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–66.
Google Scholar
Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C, Rojo R. Efficacy and safety of Abrocitinib in patients with moderate-to-severe atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatol. 2020;156(8):863–73.
Google Scholar
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, et al. JADE COMPARE investigators. Abrocitinib versus Placebo or Dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101–12.
Google Scholar
Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and safety of Abrocitinib in Combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN Randomized Clinical Trial. JAMA Dermatol. 2021;157(10):1165–73.
Google Scholar
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104–12.
Google Scholar
Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, et al. Integrated Safety Analysis of Abrocitinib for the treatment of moderate-to-severe atopic Dermatitis from the phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021;22(5):693–707.
Google Scholar
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–68.
Google Scholar
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–81.
Google Scholar
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of Upadacitinib vs Dupilumab in adults with moderate-to-severe atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatol. 2021;157(9):1047–55.
Google Scholar
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–82.
Google Scholar
Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Global allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459–66.
Google Scholar
Canadian Society of. Allergy and Immunology (CSACI). Immunotherapy Manual. 2024.
Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D. Allergen Immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55.
Google Scholar
Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110–7.
Google Scholar
Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, Pérez-Herrera LC, Chu AWL, Ceccaci R, et al. Allergen Immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2023;151(1):147–58.
Google Scholar
González-López G, Ceballos-Rodríguez RM, González-López JJ, Feito RodríguezM, Herranz-Pinto P. Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2017;177(3):688–95.
Google Scholar
Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):52.
Google Scholar
link